Cargando…
Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS)
INTRODUCTION: The effectiveness of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy (TTR-FAP) was evaluated using data from the Transthyretin Amyloidosis Outcomes Survey (THAOS) registry. METHODS: Subjects receiving tafamidis (n = 252) were compared with untreated subject...
Autores principales: | Mundayat, Rajiv, Stewart, Michelle, Alvir, Jose, Short, Sarah, Ong, Moh-Lim, Keohane, Denis, Rill, Denise, Sultan, Marla B. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5990502/ https://www.ncbi.nlm.nih.gov/pubmed/29633228 http://dx.doi.org/10.1007/s40120-018-0097-9 |
Ejemplares similares
-
Positive real-world effectiveness of tafamidis for delaying disease progression in transthyretin familial amyloid polyneuropathy
por: Stewart, Michelle, et al.
Publicado: (2015) -
Impact of genotype and phenotype on cardiac biomarkers in patients with transthyretin amyloidosis – Report from the Transthyretin Amyloidosis Outcome Survey (THAOS)
por: Kristen, Arnt V., et al.
Publicado: (2017) -
Extrapolation of Survival Benefits in Patients with Transthyretin Amyloid Cardiomyopathy Receiving Tafamidis: Analysis of the Tafamidis in Transthyretin Cardiomyopathy Clinical Trial
por: Li, Benjamin, et al.
Publicado: (2020) -
THAOS: Gastrointestinal manifestations of transthyretin amyloidosis - common complications of a rare disease
por: Wixner, Jonas, et al.
Publicado: (2014) -
Transthyretin cardiac amyloidosis in continental Western Europe: an insight through the Transthyretin Amyloidosis Outcomes Survey (THAOS)
por: Damy, Thibaud, et al.
Publicado: (2019)